Nils P Nickel, MD
Pulmonary Disease · El Paso
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Texas Tech University Health Sciences Center El Paso · 306 clinicians in this group
Hospitals listed: University Medical Center of El Paso. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Nickel’s office at (915) 215-5666 to ask if they take your plan before you enroll.
California Medical Board record
Licence A144404 · Delinquent
Licence status: Delinquent · since 2016 · expires 2022-01-31 · Medical Academy of Hannover.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas S9043Physician License · since 2020 · expires 2027-02-28ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University Medical Center of El PasoEl Paso, TXAcute Care Hospital · Physician · Has an emergency department · Birthing-friendlyPart of El Paso County Hospital DistrictPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.58 (0.78 to 2.39) · 2,319 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.441, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.142, Oct 2024 – Sep 2025
See every measure and the patient survey for University Medical Center of El Paso
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.58 (0.78 to 2.39) · 2,319 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.441 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.142 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.93 (0 to 1.96) · 518 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.31 (0.91 to 1.7) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.74 (147 to 250.49) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 31 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.7 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.3 · 364 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.7 · 2,719 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,497 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.33 (0.12 to 0.54) · 2,339 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.71 (1.45 to 5.97) · 699 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.35) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.48 (0.9 to 4.06) · 719 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.75 (1.22 to 20.28) · 92 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.89 (0.69 to 9.09) · 104 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.17) · 119 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.686 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.879 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.737 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.44 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 168 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 331 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -36.2 · 69 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 71 · 104 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 338 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.2 (4 to 9.8) · 27 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.4 to 15.9) · 27 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 119 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.4) · 360 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 97 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,426 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$32,897
Medicare paid this office $32,897 for 106 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 63 | $23,717 | $161 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,086 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $1,918 | $60 |
| Hospital discharge day management, 30 minutes or less | 11 | $736 | $61 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 13 | $213 | $13 |
Who their Medicare patients are
106 Original Medicare patients in 2024. Average age 73 · Under 65 14% · 85 and older 21% · Women 57% · Also on Medicaid 42% · Health risk score 2.52. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Diabetes 54% · Heart failure 45% · Chronic kidney disease 40% · COPD 39% · Atrial fibrillation 35% · Depression 28% · Dementia 25% · Coronary heart disease 24% · Stroke 18% · Cancer 12%.
The office billed $111,251, Medicare allowed $41,573 and paid $32,897; for 291 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 106 | 291 | 73 | 2.52 | $111,251 | $32,897 |
| 2023 | 87 | 226 | 72 | 1.82 | $95,136 | $25,833 |
| 2022 | 112 | 299 | 73 | 2.62 | $131,129 | $33,327 |
| 2021 | 123 | 380 | 71 | 1.97 | $179,299 | $49,473 |
| 2020 | 175 | 426 | 75 | 1.05 | $61,669 | $15,641 |
| 2019 | 190 | 334 | 78 | 1.02 | $61,937 | $17,070 |
| 2018 | 39 | 77 | 76 | 1.26 | $11,427 | $3,412 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Critical care, first 30-74 minutes | 43 | $18,337 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,453 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,294 | $100 |
2022: 5 services
| Critical care, first 30-74 minutes | 52 | $25,274 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $1,713 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,112 | $79 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $929 | $77 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 13 | $97 | $7 |
2021: 6 services
| Critical care, first 30-74 minutes | 75 | $41,166 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,941 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,519 | $56 |
| Test to determine lung volumes using sensors | 11 | $97 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 12 | $91 | $8 |
| Test to examine how well the lungs exchange gases | 11 | $71 | $6 |
2020: 9 services
| Return visit (30+ min) | 66 | $5,999 | $90 |
| Short return visit (20+ min) | 64 | $3,819 | $59 |
| Long return visit (40+ min) | 17 | $2,153 | $127 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $1,136 | $76 |
| Short return visit | 21 | $920 | $42 |
| Injection of drug or substance into vein | 15 | $751 | $42 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $255 | $23 |
| Injection, ceftriaxone sodium, per 250 mg | 26 | $67 | None |
| Automated urinalysis test | 23 | $52 | $2 |
2019: 6 services
| Short return visit (20+ min) | 99 | $5,979 | $60 |
| Return visit (30+ min) | 35 | $3,168 | $91 |
| Short return visit | 37 | $1,402 | $38 |
| Long return visit (40+ min) | 11 | $1,263 | $115 |
| Automated urinalysis test | 19 | $46 | $2 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $27 | None |
2018: 2 services
| Short return visit (20+ min) | 21 | $1,430 | $68 |
| Return visit (30+ min) | 14 | $1,428 | $102 |
Medicaid work
$22,760 in 2024
Medicaid paid $22,760 for 150 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 150 | $22,760 |
| 2024 | 150 | 1 | 17 | $22,760 |
| 2023 | 47 | 1 | 12 | $6,228 |
| 2022 | 135 | 1 | 22 | $21,126 |
| 2021 | 350 | 1 | 24 | $47,459 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 47 | $6,228 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 135 | $21,126 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 350 | $47,459 |
Drugs they prescribed that Part D paid
$2,196,258
Pharmacies billed $2,196,258 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 321) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
111 generic and 210 brand-name prescriptions · $2,196,258 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Adempas | 51 | $673,611 | $13,208 |
| Uptravi | 32 | $500,945 | $15,655 |
| Opsumit | 38 | $477,912 | $12,577 |
| Winrevair | 13 | $199,593 | $15,353 |
| Fluticasone-Salmeterol | 24 | $4,602 | $192 |
See all 9 drugs
| Adempas | 51 | $673,611 | $13,208 |
| Uptravi | 32 | $500,945 | $15,655 |
| Opsumit | 38 | $477,912 | $12,577 |
| Winrevair | 13 | $199,593 | $15,353 |
| Fluticasone-Salmeterol | 24 | $4,602 | $192 |
| Tadalafil | 11 | $3,994 | $363 |
| Fluconazole | 11 | $252 | $23 |
| Furosemide | 24 | $115 | $5 |
| Prednisone | 11 | $54 | $5 |
Year by year
| 2024 | 321 | 39 | 0% (0) | 65% | $2,196,258 |
| 2023 | 335 | 37 | 0% (0) | 58% | $1,975,102 |
| 2022 | 342 | 40 | None | 59% | $1,736,785 |
| 2021 | 165 | 36 | None | 49% | $668,269 |
| 2020 | 67 | 47 | None | 16% | $2,403 |
| 2019 | 66 | 59 | None | None | $2,098 |
| 2016 | 46 | 14 | 0% (0) | None | $2,561 |
| 2015 | 58 | 20 | None | None | $1,583 |
| 2014 | 14 | None | 0% (0) | None | $409 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Uptravi | 49 | $725,540 | $14,807 |
| Adempas | 47 | $655,556 | $13,948 |
| Opsumit | 18 | $232,567 | $12,920 |
| Ambrisentan | 38 | $143,216 | $3,769 |
| Tadalafil | 18 | $25,595 | $1,422 |
| Spiriva Handihaler | 13 | $9,207 | $708 |
| Advair Diskus | 14 | $6,802 | $486 |
| Fluticasone-Salmeterol | 13 | $4,421 | $340 |
| Sildenafil Citrate | 24 | $4,405 | $184 |
| Furosemide | 19 | $152 | $8 |
| Prednisone | 14 | $19 | $1 |
2022: 12 drugs
| Adempas | 37 | $449,229 | $12,141 |
| Uptravi | 37 | $413,584 | $11,178 |
| Opsumit | 31 | $343,422 | $11,078 |
| Ambrisentan | 32 | $167,092 | $5,222 |
| Letairis | 13 | $155,908 | $11,993 |
| Tadalafil | 17 | $18,348 | $1,079 |
| Sildenafil Citrate | 40 | $14,365 | $359 |
| Spiriva Handihaler | 15 | $8,924 | $595 |
| Advair Diskus | 13 | $7,010 | $539 |
| Albuterol Sulfate Hfa | 18 | $722 | $40 |
| Furosemide | 14 | $122 | $9 |
| Prednisone | 11 | $46 | $4 |
2021: 6 drugs
| Uptravi | 14 | $252,117 | $18,008 |
| Adempas | 13 | $163,189 | $12,553 |
| Ambrisentan | 11 | $77,045 | $7,004 |
| Advair Diskus | 14 | $11,236 | $803 |
| Sildenafil Citrate | 25 | $7,156 | $286 |
| Furosemide | 14 | $71 | $5 |
2020: 1 drug
| Cephalexin | 12 | $84 | $7 |
2019: 1 drug
| Cephalexin | 14 | $87 | $6 |
Money from drug and device companies
$236 in 2025
| 2025 | 4 | 5 | None | $236 |
| 2024 | 3 | 5 | None | $300 |
| 2023 | 2 | 5 | None | $161 |
| 2022 | 2 | 2 | None | $117 |
| 2021 | 1 | 1 | None | $48 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Winrevair | $108 | 1 payment
|
| Actelion Pharmaceuticals US | Uptravi | $94 | 2 payments
|
| Insmed | Arikayce | $18 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $16 | 1 payment
|
See all 5 published payments
| Actelion Pharmaceuticals US | Meals · 2025-08-27 | Uptravi | $79 |
| Merck Sharp & Dohme | Meals · 2025-07-29 | Winrevair | $108 |
| Actelion Pharmaceuticals US | Meals · 2025-05-08 | Opsumit | $15 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-06 | Ofev | $16 |
| Insmed | Meals · 2025-01-09 | Arikayce | $18 |
See earlier years (2024, 2023, 2022, 2021)
2024: $300
| United Therapeutics | Tyvaso | $256 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $28 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $15 | 1 payment
|
2023: $161
| Inari Medical | Flowtriever Catheter, S | $106 | 2 payments
|
| Actelion Pharmaceuticals US | Uptravi | $55 | 3 payments
|
2022: $117
| United Therapeutics | None | $100 | 1 payment
|
| GlaxoSmithKline | Nucala | $17 | 1 payment
|
2021: $48
| United Therapeutics | None | $48 | 1 payment
|
Professional record
- NPI
- 1528488731
- Licence
- CA A144404, TX S9043California A144404: Delinquent · expires 2022-01-31Texas S9043: Active
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207P00000X (207P00000X)
- Mailing address
- 5130 Gateway Blvd E # 51015, El Paso, TX, 79905
- NPI first listed
- 2014-04-27
- NPI last updated
- 2023-11-09
- NPI record certified
- 2023-11-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 795 El Camino Real, Palo Alto, CA, 94301